Drug Database
CL

clobetasol (clobetasol, Mipharm / Dermovate / Dermoval)

✓ Approved

Pierre Fabre S.A. · NR3C1 · Small Molecule

What is clobetasol?

clobetasol is a small molecule developed by Pierre Fabre S.A.. It is approved for therapeutic indications via topical.

Drug Profile

Brand Namesclobetasol, Mipharm, Dermovate, Dermoval
CompanyPierre Fabre S.A.
Drug ClassSmall Molecule
Molecular TargetNR3C1
RouteTopical
StatusApproved

Mechanism of Action

Molecular Targets

clobetasol acts on 1 molecular target:

NR3C1nuclear receptor subfamily 3 group C member 1 (GR, GCCR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

clobetasol is developed for 4 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Skin and subcutaneous tissue disordersDermatitis allergic✓ Approved
Skin and subcutaneous tissue disordersDermatitis atopic✓ Approved
Skin and subcutaneous tissue disordersPsoriasis✓ Approved
Skin and subcutaneous tissue disordersSeborrhoeic dermatitis✓ Approved

Related Research Articles

PubMedFrontiers in cardiovascular medicine2026-09-19

Development and external validation of an explainable machine learning model for in-hospital mortality risk stratification in intensive care unit patients with heart failure.

Xu Liusheng L, Cao Wei W, Huang Zefan Z, Lu Kefeng K et al.

Early risk stratification for in-hospital mortality remains challenging in intensive care unit (ICU) patients with heart failure (HF) because of substantial clinical heterogeneity and complex pathophysiological interactions. Explainable machine learning (ML) may offer a practical and transparent approach to prognostic assessment in this high-risk population. This retrospective dual-cohort study included 18,526 ICU patients with HF from the MIMIC-IV database (2008-2022) as the development cohort and 314 consecutive ICU patients with HF from an independent hospital-based cohort from August 1, 2023, to May 31, 2026, as the external validation cohort. Candidate predictors available within 24 h of ICU admission were screened using the Boruta algorithm and least absolute shrinkage and selection operator regression. Five ML algorithms were developed in the development cohort and compared using 5-fold nested cross-validation for internal validation. Model interpretability was assessed using Shapley Additive Explanations (SHAP). Nine routinely available predictors were retained for final model development. Among the candidate algorithms, Extreme Gradient Boosting (XGBoost) showed the most balanced overall performance and was selected as the final model. In internal validation using nested cross-validation, the XGBoost model achieved the highest validation area under the receiver operating characteristic curve (AUC), at 0.704 (95% CI 0.682-0.726). In the external validation cohort, the final model achieved an AUC of 0.877 (95% CI 0.820-0.933) and a Brier score of 0.079 (95% CI 0.061-0.099). However, this apparently stronger discrimination should be interpreted cautiously in light of cohort differences and the limited number of external events. SHAP analysis identified blood urea nitrogen, age, and white blood cell count as the most influential predictors. An explainable XGBoost-based model using nine routinely available early clinical variables showed promising performance for predicting in-hospital all-cause mortality in ICU patients with HF. This interpretable tool may support early risk stratification and individualized clinical management in critically ill patients with HF. Further large multicenter external validation is warranted.

PubMedMedicine2026-09-19

National trends in heart failure and hyperlipidemia related mortality in the United States, 1999-2024: Demographic and regional disparities with machine learning based forecasting to 2035.

Ayalew Biruk Demisse BD, Smith David N DN, Kumar Laksh L, Umar Muhammad M et al.

Cardiovascular disease remains the leading cause of death in the United States, with heart failure (HF) and hyperlipidemia substantially contributing to mortality. This study aimed to examine national trends in HF-related mortality with coexisting hyperlipidemia from 1999 to 2024 and project future mortality patterns through 2035. Mortality data were obtained from the Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research (CDC WONDER) database. Deaths were identified when heart failure and hyperlipidemia were listed on death certificates using the International Classification of Diseases, Tenth Revision (ICD-10) codes. Age-adjusted mortality rates (AAMRs) were calculated using the 2000 U.S. standard population and were stratified by sex, race/ethnicity, census region, and urbanization level. Temporal trends were evaluated using joinpoint regression analysis. Forecasts for 2025-2035 were generated using machine learning-based Seasonal Autoregressive Integrated Moving Average (SARIMA) time-series models. From 1999 to 2024, 283,161 deaths involving HF with hyperlipidemia were recorded on death certificates. The AAMR increased from 0.7 to 6.8 per 100,000 population, with a notable increase after 2018. Mortality rates were higher among men than women and were elevated in the non-Hispanic Black and American Indian/Alaska Native populations. Higher rates were also observed in nonmetropolitan counties and in the Midwest and West regions of the United States. Mortality involving HF with hyperlipidemia has increased over the past two decades, with persistent demographic and geographic differences. These findings highlight the importance of continued surveillance and targeted prevention strategies to address the cardiovascular health disparities in the United States.

PubMedMovement disorders : official journal of the Movement Disorder Society2026-09-19

Serum Metabolomic Profiles Unveil Biomarkers and Core Metabolic Pathways in Multiple System Atrophy Patients.

Wan Linlin L, Chen Zhao Z, Wan Na N, Wang Chunrong C et al.

Multiple system atrophy (MSA) is an adult-onset, fatal, neurodegenerative disease lacking mechanistic understanding, early diagnosis, and specific treatments. Metabolomics has been widely used in neurodegenerative diseases for biomarker identification and pathophysiology exploration; however its application in MSA is extremely limited. To investigate the metabolomic landscape, core metabolic pathways, and novel biomarkers for MSA. Untargeted metabolomics (ultra-high-performance liquid chromatography-Q-Exactive HF mass spectrometry [UHPLC-QE-MS]) was performed on serum samples from 85 MSA patients and 85 healthy controls (HCs). Candidate metabolites were validated via targeted metabolomics in an internal cohort (37 MSA, 36 HCs) and an external cohort (44 MSA, 44 Parkinson's disease [PD], 42 HCs). In vitro validation was performed using MO3.13 cells and SH-SY5Y cells overexpressing hSNCA. We identified 112 and 70 differential metabolites (DMs) in positive and negative modes, respectively. Pathway analysis revealed six significant pathways, including arginine and proline metabolism; pentose phosphate pathway; valine, leucine, and isoleucine biosynthesis; purine metabolism; arginine biosynthesis; and riboflavin metabolism. A riboflavin-xanthine panel effectively distinguished MSA from HCs (internal validation: [area under the curve [AUC] = 0.876), and this performance was confirmed in the external cohort (AUC = 0.943). Reduced xanthine levels in MSA patients compared with HCs and PD patients slightly enhanced the diagnostic power of neurofilament light chain for MSA-PD differentiation, boosting the AUC from 0.821 to 0.890. Both riboflavin and xanthine supplementation enhanced viability and reduced apoptosis in hSNCA-overexpressing MO3.13 cells, while only riboflavin exerted therapeutic effects in hSNCA-overexpressing SH-SY5Y cells. This study defined the serum metabolomic signature of MSA and highlighted novel biomarkers, pathological mechanisms, and therapeutic targets deserving further validation. © 2026 International Parkinson and Movement Disorder Society.

PubMedCJC open2026-09-18

Historical Drug Costs Among Elderly Patients Hospitalized with Heart Failure in Canada, 2013-2014 to 2018-2019.

Qureshi Hena H, Dover Douglas C DC, Ellis Emily E EE, Virani Sean S et al.

Heart failure (HF) management guidelines continue to evolve with emerging evidence from landmark trials defining new standards for guideline-directed medical therapy (GDMT). However, data on HF drug costs in Canada remain limited. This study examined long-term historical costs of drugs associated with HF management among elderly patients hospitalized with HF between 2013-2014 and 2018-2019. Prescription claims from the National Prescription Drug Utilization Information System were linked for patients aged > 65 years with a HF hospitalization between April 1, 2013 and March 31, 2019 in Canada, except Quebec, Nova Scotia, and the Territories. HF management drugs included GDMT and diuretics; costs were inflated to 2025 Canadian dollars. Annual total and per-patient drug costs were calculated. The total drug cost for managing HF in 163,973 elderly hospitalized patients over the 5-year period was CAD$252.2 million. Although average annual per-patient costs remained relatively stable ($567 in 2013/-2014 to $593 in 2018-2019), total annual costs rose from $31.5 million to $50.8 million, driven largely by an increase in the number of patients hospitalized with HF. GDMT accounted for the majority of drug costs, and its level of use increased from 72.2% to 76.0%. In 2018-2019, costs were higher in male patients ($632) than female patients ($558), were highest among patients aged 65-74 years ($680), and were lowest among those aged ≥ 90 years ($493). The cost of drugs to manage HF is substantial and is increasing over time, primarily as a result of the increasing number of patients being hospitalized with HF. Modest shifts occurred toward greater use of GDMT, with variations across province, sex, and age groups.

PubMedTherapie2026-09-18

Distinct pattern of reported adverse event with SGLT2 inhibitors in heart failure: A pharmacovigilance study using VigiBase data.

Chebbo Omar O, Roubille François F, Faillie Jean-Luc JL, Chapet Nicolas N et al.

Sodium-glucose cotransporter 2 inhibitors (SGLT-2i), developed for type 2 diabetes mellitus (T2DM), have been approved in symptomatic heart failure (HF). Comparison of their safety profiles between T2DM and HF remain scarce. Using international pharmacovigilance data, reported adverse events (AEs) with SGLT-2i were compared between T2DM and HF indications. Individual case safety reports (ICSRs) involving dapagliflozin or empagliflozin, both approved for T2DM and HF, were collected from the World Health Organization's pharmacovigilance database up to September 30, 2024. Five AEs of interest were specifically investigated including ketoacidosis, genitourinary infection, Fournier's gangrene, amputation and kidney failure. Reporting odds ratio (ROR) and 95% confidence interval (CI) were calculated to compare reported AEs between T2DM and HF indication. Of the 47,804 ICSRs selected, only 10.0% involved HF patients. Serious AEs accounted for 41.0% of cases in T2DM patients and 44.2% in HF patients. As expected, ketoacidosis (14.6% vs 4.1%), Fournier's gangrene (2.3% vs 1.8%), and amputation (0.5% vs 0.3%) were significantly more reported in T2DM and kidney failure was more reported in HF (6.1% vs 3.8% in T2DM). The differences were illustrated by significant ROR. However, no difference was evidenced for genitourinary tract infections between the two indications. Median time to onset of AEs was shorter in HF (111.5 days±198.7 vs 264.9±664.9 in T2DM, p<0.001) and AEs leading to death were more frequently reported in this subgroup. SGLT2 inhibitor safety profiles differ across indications, shaped in part by patient characteristics. In heart failure, the reporting of unexpected serious events, such as ketoacidosis, and a higher proportion of fatal outcomes sharply reinforces the need for intensified safety surveillance.

PubMedCJC open2026-09-18

Prevalence and Clinical Outcomes of Subclinical Atrial Fibrillation After Heart Failure Hospitalization.

Wong Jorge A JA, Mistry Priya P, Patel Ameen A, Jolly Umjeet U et al.

Subclinical atrial fibrillation (SCAF) is common in older adults, but its clinical significance in heart failure (HF) patients remains unclear. We evaluated the prevalence of SCAF in patients hospitalized with HF without prior atrial fibrillation (AF) and examined its association with HF-related outcomes. Hospitalized patients with a primary diagnosis of HF exacerbation without prior AF were prospectively recruited across 5 sites in Ontario, Canada. Participants were discharged home with 28-day continuous electrocardiogram monitoring to detect SCAF. The association between SCAF and HF readmission, cardiovascular death, and other HF-related outcomes at 1-year follow-up was determined using logistic regression models. Among 242 participants, the mean age was 70.9 ± 13.3 years; 51% were male; the mean body mass index was 31.6 ± 10.8 kg/m2; and the mean left ventricular ejection fraction was 42.3% ± 17.1%. SCAF was detected in 17 patients (7.1%), comprising 31 episodes with a median duration of 6.3 hours (interquartile range: 0.21-32.5). SCAF was associated with cardiovascular death (6 vs 28 events; adjusted odds ratio (aOR) 4.22 [95% confidence interval {CI}, 1.34-12.8]; P = 0.014) and progression to clinical AF (5 vs 14 events; aOR 8.26, [95% CI, 2.33-28.2]; P = 0.001), whereas a significant association was not observed with HF rehospitalization (4 vs 54 events; aOR 1.12 [95% CI, 0.32-3.31]; P = 0.85). In patients hospitalized with HF and no prior AF, SCAF was detected in approximately 1 in 14 individuals early after discharge and was associated with higher cardiovascular mortality and progression to clinical AF. No association with HF rehospitalization was observed, although the study may have been underpowered for this outcome. NCT03541616.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about clobetasol